Beyond the peptide category
Ibutamoren / MK-677
A non-peptide ghrelin mimetic discussed in growth-hormone research. It is not a peptide.
Non-peptide compounds · Educational information only · No medical advice
← Peptide library · Start Here
Non-peptide research compoundAlso discussed as: Ibutamoren mesylate, MK677
What it is and how it works
Ibutamoren acts as a growth-hormone secretagogue through ghrelin-related signaling. Sharing a biological pathway with certain peptides does not make a compound a peptide or establish that its clinical effects are interchangeable with theirs.
Source for this context →A closer look at the cited evidence
Human randomized trial
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- Nass et al., 2008 — ibutamoren in older adults
- Design
- Randomized, double-blind, placebo-controlled study.
- Who or what was studied
- 65 healthy adults aged 60 to 81.
- What was observed
- Growth hormone, IGF-1, and fat-free mass increased, but increased fat-free mass did not translate into improved strength or function.
- Limits of interpretation
- Body composition and function are different endpoints. Findings do not establish universal anti-aging benefit or long-term safety.
Regulatory context
This is an investigational compound rather than an FDA-approved general wellness medicine.
Safety considerations
The study reported increased fasting glucose and reduced insulin sensitivity. FDA also identifies a heart-failure safety concern in a separate patient context.
What remains uncertain
The key question is whether a biomarker or body-composition change leads to a meaningful improvement in health or function with acceptable harms. The cited trial does not establish that broader claim.